Skip to main content
. Author manuscript; available in PMC: 2007 Nov 1.
Published in final edited form as: J Emerg Med. 2007 Mar 30;32(4):349–357. doi: 10.1016/j.jemermed.2006.08.014

Table 3.

Susceptibility testing

Prior Antibiotic Use (n=99) No Prior Antibiotic Use (n=1423)
Antibiotic Tested (n) Susceptible % (95%CI) Intermed % Resistant % Tested (n) Susceptible % (95%CI) Intermed % Resistant %
Penicillins 98 49% (39−59)* 35% 16% 1404 78% (75−80)* 14% 8%
Cephalosporins§ 88 82% (72−89)* 15% 3% 1203 92% (90−93)* 6% 2%
Macrolides 53 55% (41−68)* 4% 42% 889 84% (82−87)* 1% 15%
Clindamycin 43 84% (69−93) 0% 16% 528 95% (92−96) 2% 4%
Quinolones 47 96% (84−99) 0% 4% 665 99% (98−100) <1% 1%
Tetracyclines 29 72% (53−87)* 3% 24% 454 94% (91−96)* 1% 6%
Sulfonamides 34 59% (41−75) 6% 35% 572 74% (70−77) 6% 20%
§

Cephalosporin testing includes testing for Ceftriaxone and Cefotaxime

Comparisons made between proportion susceptible among two groups.

*

Non-overlapping confidence intervals signify significant at p< 0.05 level.